Footrot

Footrot vaccine provides immunization against Dichelobacter nodosus, the primary bacterial pathogen responsible for causing infectious footrot in sheep and goats worldwide. This economically devastating disease causes severe lameness, reduced productivity, and significant welfare concerns in affected flocks and herds. The vaccine represents an important component of comprehensive footrot control programs, working alongside management practices such as foot bathing, hoof trimming, and culling of chronically infected animals to reduce disease prevalence and economic impact.

The vaccine formulation consists of killed bacterial cells or purified pilus antigens from multiple serogroups of Dichelobacter nodosus combined with oil-based adjuvants that enhance and prolong the immune response. The multivalent composition addresses the significant antigenic diversity among footrot-causing bacteria, with commercially available products typically containing ten or more serogroups to provide broad-spectrum protection against strains likely to be encountered in field conditions. This breadth of coverage is essential because immunity to one serogroup does not confer protection against others.

Available primarily in countries where footrot causes major economic losses in sheep industries, including Australia, New Zealand, the United Kingdom, and parts of Europe, footrot vaccine availability in the United States has been limited and variable. Products such as Footvax have been available through special import permits and restricted distribution channels in some regions. The regulatory status and availability should be confirmed with veterinary authorities before implementing vaccination programs, as product access varies significantly by geographic region and time.

The biological basis of footrot vaccine efficacy relies on stimulating antibody production against bacterial pili, the finger-like projections that enable Dichelobacter nodosus to attach to hoof tissue and initiate infection. Vaccinated animals develop circulating and local antibodies that interfere with bacterial attachment, reducing the likelihood of infection establishment and the severity of disease when exposure occurs. While vaccination does not provide absolute protection, it significantly reduces clinical disease incidence and supports other control measures in eradication and management programs.

The primary indication for footrot vaccination is the prevention and control of clinical footrot in sheep and goat flocks where the disease is endemic or where infection pressure remains high despite other control measures. Vaccination is most valuable as part of integrated control programs combining immunization with foot bathing, hoof trimming, segregation of affected animals, and strategic culling of chronically infected carriers. Used alone, vaccination provides incomplete protection, but combined with other measures, it significantly accelerates progress toward disease elimination.

In endemic flocks with established footrot problems, vaccination helps reduce the prevalence of clinical disease, decrease transmission rates, and protect susceptible animals during high-risk periods. The disease spreads most rapidly during warm, wet conditions that soften hoof tissue and support bacterial survival in the environment. Strategic vaccination timed before predictable high-risk seasons helps build population immunity when protection is most needed, reducing the clinical and economic impact of seasonal disease peaks.

Footrot vaccination serves important roles in eradication programs aimed at eliminating the disease from individual properties or regional populations. By reducing the proportion of animals developing clinical lesions and shedding bacteria, vaccination decreases environmental contamination and transmission pressure. This reduction in disease dynamics, combined with identification and removal of persistently infected animals, creates conditions favorable for achieving and maintaining disease-free status.

New flock establishments and farms introducing animals from external sources benefit from vaccination as part of biosecurity protocols. Animals entering a property should be vaccinated and quarantined to allow immune response development before mixing with the resident flock. This practice helps prevent introduction of footrot to previously clean properties and reduces the risk of disease amplification when carrier animals inadvertently enter the flock.

Show and sale animals warrant vaccination consideration due to the elevated exposure risk associated with commingling at events and the economic impact of lameness on animal presentation and value. Visible lameness disqualifies animals from exhibition and significantly reduces buyer interest and sale prices. Timely vaccination before show seasons protects valuable breeding stock and market animals from this economically devastating disease.

Footrot vaccine administration follows standard subcutaneous injection protocols, with specific dosing and timing recommendations varying by product formulation. The typical dose for commercially available products is 1 mL administered subcutaneously, though label directions for specific products should always be followed precisely. Injection sites should be clean, dry, and free of contamination to prevent injection site infections that could confound disease assessment.

The preferred injection site for footrot vaccines in sheep and goats is the lateral neck region, posterior to the ear and anterior to the shoulder. This location allows easy access for administration, permits monitoring of injection site reactions, and avoids areas of the carcass valuable for meat production. Subcutaneous administration requires lifting a fold of loose skin and inserting the needle parallel to the body surface to deposit vaccine in the space between skin and underlying muscle.

Primary vaccination protocols for previously unvaccinated animals typically require two doses administered four to six weeks apart to establish protective immunity. The initial dose primes the immune system, while the second dose stimulates the amplified secondary immune response that provides durable protection. Animals receiving only a single dose may develop partial immunity insufficient for reliable protection, making completion of the primary series essential for program success.

Annual booster vaccination maintains immunity in previously vaccinated animals and should be timed strategically relative to anticipated disease risk periods. In regions with predictable seasonal footrot patterns, booster vaccination four to six weeks before the onset of high-risk conditions allows protective antibody levels to peak when exposure pressure is greatest. Flocks in eradication programs may benefit from twice-yearly boosters during intensive control phases.

Newly purchased animals should receive vaccination immediately upon arrival with a booster four to six weeks later regardless of reported vaccination history from the source property. This practice accounts for uncertainty about previous vaccine products, administration quality, and potential serogroup mismatches between vaccines used at different locations. Quarantine periods should extend until the primary vaccination series is complete and immunity has developed.

Withdrawal time requirements for footrot vaccines vary by product and jurisdiction but are generally minimal for killed bacterial vaccines. However, producers should verify label withdrawal specifications for specific products, as some oil-adjuvanted formulations may require extended periods before slaughter. Meat withdrawal times of 21 to 60 days are common for adjuvanted products, with specific requirements determined by regulatory authorities in each market.

Injection site reactions represent the most commonly observed adverse effects following footrot vaccination, particularly with oil-adjuvanted formulations designed to enhance immune response duration. Local swelling at the injection site typically appears within 24 to 48 hours following vaccination and may persist for several days to weeks depending on individual animal response and vaccine formulation. The swelling may be firm to fluctuant and may cause mild discomfort but should not significantly impair the animal's movement or behavior.

Transient systemic reactions including mild fever, decreased appetite, and lethargy may occur in the first 24 to 72 hours following vaccination. These general signs reflect normal immune activation and typically resolve without intervention. Animals experiencing systemic reactions should be monitored to ensure recovery proceeds normally and to identify any individuals developing more serious complications requiring veterinary attention.

Granuloma formation at injection sites occurs in some animals, particularly following administration of strongly adjuvanted vaccine formulations. These persistent nodules may remain palpable for months after vaccination and occasionally persist indefinitely. While usually of no clinical significance, granulomas can cause carcass trimming losses at slaughter and may raise concerns about injection site management practices. Proper injection technique using appropriate needle length and ensuring truly subcutaneous rather than intramuscular deposition helps minimize granuloma formation.

Hypersensitivity reactions ranging from localized urticaria to systemic anaphylaxis have been reported following footrot vaccination, though serious allergic reactions are uncommon. Animals with previous vaccine exposure are at greater risk of hypersensitivity reactions than those receiving primary immunization. Any animal showing signs of acute allergic reaction including facial swelling, respiratory distress, or collapse requires immediate treatment with epinephrine and supportive care. Having epinephrine available during vaccination sessions allows rapid response to anaphylactic events.

Abortion has been occasionally associated with vaccination of pregnant animals, though direct causation is difficult to establish. The stress of handling and restraint during vaccination, injection site discomfort, or transient systemic reactions may contribute to pregnancy loss in susceptible animals. Many producers elect to vaccinate breeding stock before breeding or during early pregnancy rather than during late gestation to minimize potential reproductive impacts while maintaining herd immunity.

Footrot vaccination is contraindicated in animals with known hypersensitivity to vaccine components, including the bacterial antigens, adjuvant materials, or preservatives present in specific formulations. Animals that have experienced previous allergic reactions to footrot vaccines should not be revaccinated with the same product, though alternative formulations with different adjuvant systems may be tolerated in some cases. Complete avoidance of vaccination may be necessary for truly hypersensitive individuals.

Severely debilitated or clinically ill animals should not be vaccinated until their condition has stabilized and they have recovered sufficiently to mount an appropriate immune response. Animals with systemic infections, severe parasitism, malnutrition, or other conditions causing immunosuppression may fail to develop protective immunity and face increased risk of adverse reactions. Deferring vaccination until health is restored ensures better outcomes for both individual animals and flock immunity levels.

Animals currently receiving immunosuppressive medications including corticosteroids should not be vaccinated until therapy is completed and immune function has recovered. A minimum washout period of two weeks following discontinuation of immunosuppressive treatments is generally recommended before vaccination. The decision to vaccinate animals with ongoing immunosuppressive therapy for chronic conditions should involve veterinary consultation to balance disease prevention needs against reduced vaccine efficacy.

Vaccination of animals in the immediate pre-slaughter period should be avoided for products with withdrawal time requirements. Beyond regulatory compliance, injection site reactions developing post-vaccination may not resolve before slaughter, causing carcass defects and trimming losses. Producers should schedule vaccination activities to allow adequate time for reaction resolution and meat withdrawal compliance before anticipated marketing dates.

Concurrent administration of multiple vaccines is common in sheep and goat management programs and is generally considered safe when vaccines are administered at separate injection sites. Footrot vaccine may be given during the same handling session as clostridial vaccines, respiratory disease vaccines, and other routine immunizations without significant interaction concerns. However, administering multiple vaccines at the same body location should be avoided to allow differentiation of injection site reactions and prevent potential interference between adjuvant systems.

Antibiotic therapy for active footrot or other bacterial infections does not directly interfere with response to killed bacterial vaccines, as the vaccine does not contain live organisms that could be affected by antimicrobial agents. However, animals requiring antibiotic treatment may be systemically compromised in ways that reduce their ability to mount optimal immune responses. When possible, completing antibiotic therapy and allowing recovery before vaccination ensures better immunization outcomes.

Anti-inflammatory medications including corticosteroids and non-steroidal anti-inflammatory drugs may reduce the immune response to vaccination if administered concurrently. The immunomodulatory effects of corticosteroids are particularly significant and may substantially impair antibody production following vaccination. If anti-inflammatory therapy is necessary during the vaccination period, veterinary guidance should be sought regarding optimal timing of vaccination relative to treatment.

Parasiticides including anthelmintics and ectoparasiticides do not interact directly with footrot vaccines and may be administered according to routine schedules. However, heavy parasite burdens may compromise immune function and reduce vaccine response, making strategic parasite control before vaccination beneficial for optimal outcomes. Ensuring animals are in good nutritional status and free of heavy parasite loads supports the immune response necessary for protective immunity development.

Operator safety during vaccine handling and administration requires attention to proper technique and protective measures. Oil-adjuvanted footrot vaccines can cause persistent inflammatory reactions if accidentally self-injected, resulting in painful granulomatous lesions that may require surgical drainage or excision. Personnel administering vaccine should use appropriate needle safety devices, maintain careful attention during injection, and avoid recapping needles after use. Any accidental human injection should receive prompt medical evaluation.

Vaccination alone does not provide complete protection against footrot and should not be relied upon as the sole control measure in endemic situations. Comprehensive footrot management requires integration of vaccination with environmental management, foot bathing, hoof trimming, identification and treatment of affected animals, and strategic culling of chronic carriers. Producers who implement vaccination without addressing other disease maintenance factors may be disappointed with results and may incorrectly conclude that vaccination is ineffective.

Serogroup matching between vaccine and field strains influences protection levels, as immunity is largely serogroup-specific. Commercial vaccines contain multiple serogroups to provide broad coverage, but field strains may occasionally belong to serogroups not represented in the vaccine. In flocks experiencing vaccination failures despite good program compliance, laboratory identification of circulating serogroups may reveal mismatches requiring alternative vaccination approaches or autogenous vaccine consideration.

Proper vaccine storage and handling ensures maintained potency and efficacy at administration. Footrot vaccines should be stored under refrigeration according to label directions and protected from freezing, which destroys vaccine integrity. Products should be inspected before use for abnormal color, consistency, or particulate matter that might indicate degradation. Expired products should never be used, as efficacy cannot be guaranteed beyond the labeled dating period.

Record keeping for vaccination programs supports disease management decisions, regulatory compliance, and troubleshooting of program failures. Documentation should include product identification, lot numbers, administration dates, animal identification, injection sites, and any observed adverse reactions. These records prove invaluable when evaluating program success, investigating disease outbreaks in vaccinated animals, or reporting adverse events to manufacturers and regulatory authorities.

Footrot vaccines require refrigerated storage at temperatures between 2°C and 8°C (35°F to 46°F) from manufacture through administration to maintain product potency and safety. Temperature excursions outside this range, particularly freezing, may denature vaccine antigens or destabilize adjuvant emulsions, rendering the product ineffective or potentially harmful. Refrigerator thermometers should be monitored regularly and refrigeration equipment maintained properly to ensure consistent temperature control throughout product storage.

Product handling during vaccination sessions should maintain cold chain integrity to the extent practical. Vaccines should be transported to the working area in insulated coolers with ice packs and returned to refrigeration promptly between groups if extended breaks occur. Multi-dose vials should be withdrawn only with sterile needles, and a new needle should be used for each animal to prevent cross-contamination of the vial contents. Opened multi-dose vials should be used within the timeframe specified on product labeling, typically within 24 hours of first withdrawal.

Disposal of unused vaccine, expired products, and administration equipment should follow local regulations for biological and sharps waste. Many jurisdictions require specific disposal procedures for veterinary vaccines and used needles. Unused vaccine should not be disposed of through standard trash or wastewater systems. Producers should establish relationships with veterinary clinics or waste disposal services capable of handling biological materials appropriately. Maintaining disposal records may be required for regulatory compliance in some areas.

Breed susceptibility to footrot varies among sheep populations, with some breeds demonstrating greater resistance to infection and clinical disease than others. Merino and Merino-derived breeds are generally considered more susceptible to footrot than British breeds such as Suffolk, Hampshire, and Dorset. However, all breeds can be affected under conditions favorable for disease transmission, and vaccination should be considered based on flock disease history and risk assessment rather than breed alone.

Hair sheep breeds including Katahdin, St. Croix, and Barbados Blackbelly may show different footrot patterns compared to wool breeds, though they remain susceptible to infection and benefit from vaccination in endemic environments. The smaller, harder hooves characteristic of some hair sheep breeds may offer slight mechanical resistance to infection, but this does not substitute for proper disease prevention measures including vaccination where indicated.

Goat breeds demonstrate generally similar vaccine responses across dairy, meat, and fiber types, though management differences among these production systems may influence vaccination program design. Dairy goat operations with intensive management and frequent animal handling may achieve better vaccination compliance than extensive meat goat operations where animal contact is limited. Angora goats with intensive fiber production requirements warrant careful attention to any production impacts from vaccine reactions.

Genetic selection for footrot resistance represents an emerging complementary strategy to vaccination, with research identifying genetic markers associated with reduced susceptibility. Some producers are incorporating footrot resistance into breeding objectives alongside production traits. However, genetic resistance development requires long-term selection commitment and does not substitute for vaccination in currently susceptible populations. Integrating vaccination with gradual genetic improvement offers optimal long-term disease management for forward-thinking operations.

Zinc sulfate foot bathing solutions complement vaccination as primary tools in footrot control programs. Foot baths containing 10-20% zinc sulfate provide both treatment for active infections and preventive hardening of hoof tissue that reduces susceptibility to new infections. Regular foot bathing during high-risk periods combined with vaccination provides synergistic protection exceeding either measure alone. Copper sulfate foot baths offer an alternative where zinc sulfate is unavailable or ineffective.

Systemic antibiotics including penicillin, oxytetracycline, and erythromycin are used therapeutically to treat active footrot infections and may be combined with vaccination programs to reduce disease prevalence in infected flocks. Antibiotic therapy addresses current infections while vaccination builds immunity against future exposure. Long-acting formulations provide extended tissue levels that support bacterial elimination from infected hoof tissue over treatment courses typically lasting several weeks.

Topical antimicrobial preparations including tetracycline sprays and zinc-based ointments provide adjunctive therapy for individual lesion treatment alongside vaccination programs. These products are applied directly to affected hooves following trimming and cleaning, providing local antimicrobial activity that complements systemic immunity developed through vaccination. Regular hoof inspection and topical treatment of early lesions prevents progression to severe clinical disease in vaccinated animals exposed to high bacterial challenge.